From June 20 to 23, 2025, the 85th Scientific Sessions of the American Diabetes Association (ADA) convened in Chicago, USA
Semaglutide is administered via a subcutaneous injection once a week using a pre-filled pen
Food and Drug Administration (FDA) announced today that it is proposing a new rule to stop the use of an ingredient in popular over-the-counter (OTC) cold and allergy medications
The ability of the MD to reduce visceral adiposity while preserving LBM may have important implications in the context of semaglutide therapy, which is known to reduce overall fat but, in some rare cases, also to associate with a LBM loss [68, 69]
[DOI] [PubMed] [Google Scholar] 31.Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jdar E., Leiter L.A., Lingvay I., Rosenstock J., Seufert J., Warren M.L., SUSTAIN-6 Investigators Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
The scale reflects total body weight